Endpoints News

Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblix

Published

2 weeks ago

on

Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals and its investigational treatment for chronic myeloid leukemia.

The Wednesday morning M&A move gives the New Jersey …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version